CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Aclaris Therapeutics Q3 revenue beats analyst estimates

By Reuters News


Overview

  • US biopharma firm's Q3 revenue declined yr/yr but beat analyst expectations

  • Q3 net loss widened yr/yr but was smaller than analysts expected

  • Company expects cash to fund operations through first half of 2029


Outlook

  • Aclaris expects to initiate Phase 2b trial of modzatinib in lichen planus in Q4 2026

  • Company reaffirms timeline for top line results from Phase 2 ADMIRATION trial of bosakitug in AD

  • Aclaris expects cash runway to fund operations through the first half of 2029


Result Drivers

  • ATI-052 DEVELOPMENT COSTS - Co said higher R&D expenses were mainly due to manufacturing and clinical costs for ATI-052 in AD and asthma

  • SUN PHARMA MILESTONE IMPACT - Co said revenue decline was mainly due to a sales milestone achieved under Sun Pharma license agreement in prior year

  • INCREASED G&A EXPENSES - Co attributed higher G&A costs to increased professional, legal, personnel and stock-based compensation expenses


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.48 mln

$1.30 mln (10 Analysts)

Q3 Net Loss

Beat

$18.51 mln

$23.68 mln (11 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Aclaris Therapeutics, Inc. is $9.50, about 158.2% above its November 4 closing price of $3.68


Reuters Recommended Reads

  • Nov 4 - Dianthus Therapeutics Q3 net loss widens as clinical spending rises; sees MMN data in December

  • Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

  • Nov 4 - Aprea Therapeutics Q3 net loss widens on higher R&D spending


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.